antibody

BRCA2 Monoclonal Antibody

MBS190078

0.1 ml

420 USD

monoclonal

mouse

nonconjugated

Antibody

BRCA2 Monoclonal Antibody

BRCA2

Anti-BRCA2; BRCA2

brca2; Breast cancer type 2 susceptibility protein; breast cancer type 2 susceptibility protein; OTTHUMP00000018803; fanconi anemia group D1 protein; breast cancer 2 tumor suppressor; BRCA1/BRCA2-containing complex, subunit 2; breast cancer susceptibility protein BRCA2; breast and ovarian cancer susceptibility gene, early onset; breast cancer 2, early onset; Fanconi anemia group D1 protein

BRCA2; BRCA2; FAD; FACD; FAD1; GLM3; BRCC2; FANCB; FANCD; PNCA2; FANCD1; BROVCA2; FACD; FANCD1

BRCA2_HUMAN

Monoclonal

IgG1 kappa

Mouse

3418

Anti-BRCA2 [Murine MAb recognizes BRCA2, a 390 kD nuclear protein with tumor suppressor activity that functions in DNA recombination and double strand break repair.]. This antibody recognizes human BRCA2, a 390 kD nuclear protein. BRCA2 has been associated with predisposition of women to early-onset breast and ovarian cancers. BRCA2 appears to be involved in DNA recombination and double strand break repair.

100 ug Protein G-purified antibody in PBS, pH 7.4

This antibody is stable for at least one (1) year at -70 degree C. Avoid multiple freeze thaw cycles.

Immunoblot

Immunoblotting: use at 1-5 ug/ml. Positive control: Molt 4 cells.

Antigen: GST fusion protein expressedin E. coli corresponding to aa 2336-2478 of human BRCA2.

Stabilizer: None. Preservatives: None. Available on request. Dilutions Instructions: Dilute in PBS or medium which is identical to that used in the assay system.

Cancer Research Products

Chen, P-L et al. 1998. PNAS (USA)95: 5287-5292.

1177438

CAA64484.1

P51587

384,225 Da

DNA Repair Pathway 105837!!Double-Strand Break Repair Pathway 105861!!FOXM1 Transcription Factor Network Pathway 137935!!Fanconi Anemia Pathway 105895!!Homologous DNA Pairing And Strand Exchange Pathway 105870!!Homologous Recombination Repair Pathway 105862!!Homologous Recombination Pathway 83046!!Homologous Recombination Pathway 454!!Homologous Recombination Repair Of Replication-independent Double-strand Breaks Pathway 105863!!Meiotic Recombination Pathway 205242

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq]

Function: Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. Ref.6 Ref.7 Ref.10 Ref.15 Ref.16 Ref.17. Subunit structure: Monomer and dimer. Interacts with RAD51 and DSS1. Interacts with ubiquitinated FANCD2. Interacts with WDR16. Interacts with USP11. Interacts with DMC1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein. Ref.6 Ref.7 Ref.8 Ref.11 Ref.12 Ref.15 Ref.16 Ref.17. Tissue specificity: Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen. Post-translational modification: Phosphorylated by ATM upon irradiation-induced DNA damage. Ref.7 Ref.13Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation. Ref.8. Involvement in disease: Defects in BRCA2 are a cause of susceptibility to breast cancer (BC) [. MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Ref.12 Ref.24 Ref.25 Ref.26 Ref.27 Ref.30 Ref.31 Ref.33 Ref.34 Ref.35 Ref.36 Ref.38 Ref.43 Ref.44 Ref.45 Ref.48 Ref.52 Ref.53 Ref.55 Ref.57Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [. MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. Ref.5Defects in BRCA2 are a cause of susceptibility to breast-ovarian cancer familial type 2 (BROVCA2) [. MIM:612555]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate.Defects in BRCA2 are the cause of Fanconi anemia complementation group D type 1 (FANCD1) [. MIM:605724]. It is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. Ref.46 Ref.51 Ref.60Defects in BRCA2 are a cause of glioma type 3 (GLM3) [. MIM:613029]. Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. Ref.9. Sequence similarities: Contains 8 BRCA2 repeats.

0.1 ml

420 USD